Subscribe to the gold package and get unlimited access to Shamra Academy
Register a new userDistributions of positron-emitting nuclei in proton and carbon-ion therapy studied with GEANT4
64
0
0.0
(
0
)
Ask ChatGPT about the research
No Arabic abstract
Depth distributions of positron-emitting nuclei in PMMA phantoms are calculated within a Monte Carlo model for Heavy-Ion Therapy (MCHIT) based on the GEANT4 toolkit (version 8.0). The calculated total production rates of $^{11}$C, $^{10}$C and $^{15}$O nuclei are compared with experimental data and with corresponding results of the FLUKA and POSGEN codes. The distributions of e$^+$ annihilation points are obtained by simulating radioactive decay of unstable nuclei and transporting positrons in surrounding medium. A finite spatial resolution of the Positron Emission Tomography (PET) is taken into account in a simplified way. Depth distributions of $beta^+$-activity as seen by a PET scanner are calculated and compared to available data for PMMA phantoms. The calculated $beta^+$-activity profiles are in good agreement with PET data for proton and $^{12}$C beams at energies suitable for particle therapy. The MCHIT capability to predict the $beta^+$-activity and dose distributions in tissue-like materials of different chemical composition is demonstrated.
rate research
Read More
We study the propagation of nucleons and nuclei in tissue-like media within a Monte Carlo Model for Heavy-ion Therapy (MCHIT) based on the GEANT4 toolkit (version 8.2). The model takes into account fragmentation of projectile nuclei and secondary interactions of produced nuclear fragments. Model predictions are validated with available experimental data obtained for water and PMMA phantoms irradiated by monoenergetic carbon-ion beams. The MCHIT model describes well (1) the depth-dose distributions in water and PMMA, (2) the doses measured for fragments of certain charge, (3) the distributions of positron emitting nuclear fragments produced by carbon-ion beams, and (4) the energy spectra of secondary neutrons measured at different angles to the beam direction. Radial dose profiles for primary nuclei and for different projectile fragments are calculated and discussed as possible input for evaluation of biological dose distributions. It is shown that at the periphery of the transverse dose profile close to the Bragg peak the dose from secondary nuclear fragments is comparable to the dose from primary nuclei.
A Geant4-based Monte Carlo model for Heavy-Ion Therapy (MCHIT) is used to study radiation fields of H-1, He-4, Li-7 and C-12 beams with similar ranges (~160-180 mm) in water. Microdosimetry spectra are simulated for wall-less and walled Tissue Equivalent Proportional Counters (TEPCs) placed outside or inside a phantom, as in experiments performed, respectively, at NIRS, Japan and GSI, Germany. The impact of fragmentation reactions on microdosimetry spectra is investigated for He-4, Li-7 and C-12, and contributions from nuclear fragments of different charge are evaluated for various TEPC positions in the phantom. The microdosimetry spectra measured on the beam axis are well described by MCHIT, in particular, in the vicinity of the Bragg peak. However, the simulated spectra for the walled TEPC far from the beam axis are underestimated. Relative Biological Effectiveness (RBE) of the considered beams is estimated using a modified microdosimetric-kinetic model. Calculations show a similar rise of the RBE up to 2.2-2.9 close to the Bragg peak for helium, lithium and carbon beams compared to the modest values of 1-1.2 at the plateau region. Our results suggest that helium and lithium beams are also promising options for cancer therapy.
It is well known from numerous experiments that nuclear multifragmentation is a dominating mechanism for production of intermediate-mass fragments in nucleus-nucleus collisions at energies above 100 A MeV. In this paper we investigate the validity and performance of the Fermi break-up model and the statistical multifragmentation model implemented as parts of the Geant4 toolkit. We study the impact of violent nuclear disintegration reactions on the depth-dose profiles and yields of secondary fragments for beams of light and medium-weight nuclei propagating in extended media. Implications for ion-beam cancer therapy and shielding from cosmic radiation are discussed.
We study the spatial distributions of $beta^+$-activity produced by therapeutic beams of $^3$He and $^{12}$C ions in various tissue-like materials. The calculations were performed within a Monte Carlo model for Heavy-Ion Therapy (MCHIT) based on the GEANT4 toolkit. The contributions from $^{10,11}$C, $^{13}$N, $^{14,15}$O, $^{17,18}$F and $^{30}$P positron-emitting nuclei were calculated and compared with experimental data obtained during and after irradiation. Positron emitting nuclei are created by $^{12}$C beam in fragmentation reactions of projectile and target nuclei. This leads to a $beta^+$-activity profile characterised by a noticeable peak located close to the Bragg peak in the corresponding depth-dose distribution. On the contrary, as the most of positron-emitting nuclei are produced by $^3$He beam in target fragmentation reactions, the calculated total $beta^+$-activity during or soon after the irradiation period is evenly distributed within the projectile range. However, we predict also the presence of $^{13}$N, $^{14}$O, $^{17,18}$F created in charge-transfer reactions by low-energy $^3$He ions close to the end of their range in several tissue-like media. The time evolution of $beta^+$-activity profiles was investigated for both kinds of beams. Due to the production of $^{18}$F nuclide the $beta^+$-activity profile measured 2 or 3 hours after irradiation with $^{3}$He ions will have a distinct peak correlated with the maximum of depth-dose distribution. We found certain advantages of low-energy $^{3}$He beams over low-energy proton beams for reliable PET monitoring during particle therapy of shallow located tumours. In this case the distal edge of $beta^+$-activity distribution from $^{17}$F nuclei clearly marks the range of $^{3}$He in tissues.
This manuscript provides a response to a recent report by Mazzone et al. available online on arXiv that, in turn, tentatively aims at demonstrating the inefficacy of proton boron capture in hadrotherapy. We clarify that Mazzone et al. do not add any scientific or technical insights to the points extensively discussed in the original manuscript by Cirrone et al., and/or in the series of iterations had with the Referee, which ultimately lead to the publication of our original and pioneering experimental work. Here we summarize some of the key points of the long scientific debate we had during the review process of paper by Cirrone et al., which are very similar to the considerations presented by Mazzone et al.. In conclusion, no quantitative explanation of our robust experimental achievements presented in Cirrone et al. is provided in Mazzone et al.
Log in to be able to interact and post comments
comments
Fetching comments
Sign in to be able to follow your search criteria
